000			01430 a2200385 4500
005			20250512001012.0
264		0	_c19860305
008			198603s 0 0 eng d
022			_a0160-2446
024	7		_a10.1097/00005344-198511000-00009 _2doi
040			_aNLM _beng _cNLM
100	1		_aKramer, J B
245	0	0	_aThromboxane A2 does not contribute to arrhythmogenesis during evolving canine myocardial infarction. _h[electronic resource]
260			_bJournal of cardiovascular pharmacology _c
300			_a1069-76 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAction Potentials _xdrug effects
650	0	4	_aAnimals
650	0	4	_aArrhythmias, Cardiac _xetiology
650	0	4	_aBlood Pressure _xdrug effects
650	0	4	_aDogs
650	0	4	_aElectric Stimulation
650	0	4	_aHeart Conduction System _xdrug effects
650	0	4	_aHeart Rate _xdrug effects
650	0	4	_aIn Vitro Techniques
650	0	4	_aMyocardial Infarction _xcomplications
650	0	4	_aThromboxane A2 _xpharmacology
700	1		_aDavis, A G
700	1		_aDean, R
700	1		_aMcCluskey, E R
700	1		_aNeedleman, P
700	1		_aCorr, P B
773	0		_tJournal of cardiovascular pharmacology _gvol. 7 _gno. 6 _gp. 1069-76
856	4	0	_uhttps://doi.org/10.1097/00005344-198511000-00009 _zAvailable from publisher's website
999			_c2424350 _d2424350